secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0001789769-23-000020
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio cuts US headcount to ~15, consolidates operations to UK, expects cash runway beyond 2026
--------------------------------------------------------------------------------

- Will extend reduction-in-force to ~15 US employees; transition ITIL-306 manufacturing and trial to Manchester, UK.
- Estimates total restructuring costs up to $3.0M, excluding potential facility sale charges.
- Evaluating potential sale/sublease of Tarzana, CA manufacturing site to further extend cash runway.
- Expects cash runway beyond 2026; initial ITIL-306 clinical data still expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000020/0001789769-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000020/til-20230130.htm
  HTML page:      https://secwatch.observer/filing/0001789769-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer